Prothena H1 Net Income $14.1M; Q2 Loss Narrows to $(18.6)M

Prothena reported a net income of $14.1 million for the first six months of 2026, a substantial improvement from a net loss of $186.0 million in the same period last year, primarily driven by $50.1 million in license revenue. The company's total revenue for H1 2026 increased to $52.1 million from $7.2 million in H1 2025, while R&D expenses significantly decreased. For the second quarter of 2026, the net loss narrowed to $(18.6) million from $(125.8) million in Q2 2025. The company ended the period with $288.2 million in cash and cash equivalents and repurchased $22.5 million in ordinary shares.